Cosibelimab - Complete Guide to Precautions for Use of UNLOXCYT

Cosibelimab (UNLOXCYT) is a programmed death ligand -1 (PD-L1) blocking antibody that activates the immune system to attack cancer cells by blocking the binding of PD-L1 and PD-1. The drug is indicated for the treatment of adult patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced cutaneous squamous cell carcinoma (laCSCC), particularly those who are not candidates for curative surgery or radical radiotherapy. In December 2024, cosibelimab was officially approved by the U.S. Food and Drug Administration (FDA) and became an important option for the treatment of cutaneous squamous cell carcinoma.

Before using cosibelimab, patients need to be comprehensively evaluated by a professional doctor, including their condition, physical condition and past medical history, to ensure the suitability and safety of the drug. And special attention needs to be paid to the patient's immune system status, risk of infection, and whether there are autoimmune diseases.

The recommended dose of cosibelimab is 1200 mg administered by intravenous infusion every 3 weeks over approximately 60 minutes; treatment should be continued until disease progression or unacceptable toxicity occurs. During the infusion process, medical staff need to closely monitor the patient's vital signs, such as blood pressure, heart rate, etc., to promptly detect and deal with possible allergic reactions or other abnormalities. Patients need to be observed for at least 30 minutes after infusion to ensure that no acute adverse reactions occur.

Cosibelimab may cause common adverse reactions such as fatigue, rash, diarrhea, and hypothyroidism, as well as serious immune-related adverse reactions such as pneumonia, hepatitis, and colitis. Patients need to pay close attention to their own conditions. If they experience severe discomfort, they should communicate with their doctor immediately and adjust the treatment plan if necessary.

It is important to note that there is currently insufficient data to support the safety of cosibelimab in pregnant and lactating women and should be used with caution. This drug has not been clinically tested in people under the age of 18 and is not recommended for use. When elderly patients use cosibelimab, the treatment plan needs to be adjusted according to their physical condition and monitoring must be strengthened.

cosibelimab-UNLOXCYTIt provides a new treatment option for patients with cutaneous squamous cell carcinoma, but its use must strictly follow the recommended dosage and usage and be conducted under the guidance of a professional doctor. Patients should fully understand the potential risks of drugs, pay close attention to their own conditions, and communicate with their doctors in a timely manner. Through scientific management and timely intervention, the therapeutic effect of drugs can be maximized while reducing the risk of adverse reactions.

https://ir.checkpointtx.com/news-events/press-releases/detail/127/checkpoint-therapeutics-announces-fda-approval-of